Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019
February 28 2019 - 7:00AM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that three
abstracts will be presented at the American Association for Cancer
Research (AACR) Annual Meeting 2019, which will be held from March
29 through April 3, 2019 in Atlanta, GA. Presentations will
highlight the company’s lead programs, STING agonist ADU-S100, and
anti-APRIL antibody BION-1301.
Details of the presentations are as follows:
|
|
|
Abstract 1202: |
|
Tumor cell intrinsic STING signaling
demonstrates minimal contribution to
the anti-tumor response elicited by the STING
agonist ADU-S100 (MIW815) |
|
|
|
Session: |
|
Tumor-immune Interactions |
Date/Time: |
|
Monday Apr 1, 2019 8:00 AM - 12:00 PM |
Location: |
|
Georgia World Congress Center, Exhibit Hall B,
Poster Section 9 |
|
|
|
Abstract CT107: |
|
Phase 1/2 Safety and Pharmacokinetics of
BION-1301 Targeting APRIL,
a Proliferation-Inducing Ligand, in Adults
with Relapsed or Refractory
Multiple Myeloma |
|
|
|
Session: |
|
Phase I-III Trials in Progress: Part 1 |
Date/Time: |
|
Monday Apr 1, 2019 1:00 PM - 5:00 PM |
Location: |
|
Georgia World Congress Center, Exhibit Hall B,
Poster Section 17 |
|
|
|
Abstract 1203: |
|
Preclinical development of ADU-1805, a
highly selective pan-allele anti-SIRPα antibody that blocks the
SIRPα-CD47 innate immune checkpoint |
|
|
|
Session: |
|
Tumor-immune Interactions |
Date/Time: |
|
Monday, Apr 1, 2019 8:00 AM - 12:00 PM |
Location: |
|
Georgia World Congress Center, Exhibit Hall B,
Poster Section 9 |
|
|
|
To view these abstracts, please visit the AACR website located
at http://www.aacr.org/Meetings
About Aduro Aduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body's natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a fully blocking monoclonal antibody that blocks APRIL
binding to both the BCMA and TACI receptors, is being evaluated in
multiple myeloma and as a potential treatment for IgA nephropathy.
Aduro is collaborating with a number of leading global
pharmaceutical companies to help expand and drive its product
pipeline. For more information, please
visit www.aduro.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our technology.
In some cases, you can identify these statements by forward-looking
words such as “may,” “will,” “continue,” “anticipate,” “intend,”
“could,” “project,” “expect” or the negative or plural of these
words or similar expressions. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
early or preliminary clinical trial results may not be predictive
of future results, our history of net operating losses and
uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technologies to build a pipeline of
product candidates, our ability to obtain and maintain regulatory
approval of our product candidates, our ability to operate in a
competitive industry and compete successfully against competitors
that have greater resources than we do, our reliance on third
parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our annual report on Form 10-K for the
year ended December 31, 2018, which is on file with the Securities
and Exchange Commission. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
|
|
|
Investor Relations Contact: |
|
Media Contact: |
Noopur Liffick |
|
Aljanae Reynolds |
510-809-2465 |
|
510-809-2452 |
investors@aduro.com |
|
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024